On the other hand, despite the fact that amplification of KRAS was described in RCC, as reported for c-MYC [101], mutations in RAS and BRAF are extremely rare in kidney tumors (almost 1%) [102,103,104]. The gene discussed is KRAS; the disease is renal cell carcinoma.